Drug Trial Radar · NCT06837259
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Mar 19, 2025
Primary completion
Jun 11, 2025
Study completion Jun 11, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effect of cyclosporine, an immunosuppressant (medicine that suppresses the immune system), on the pharmacokinetics (PK) of PF-07328948 in healthy participants (Part A). The study may also estimate the effect of clarithromycin, an antibiotic, on the PK of PF-07328948 in healthy participants (Part B is optional). This study is seeking participants who: * are 18 years of age or older * are male or female who are not of childbearing potential * are healthy (do not have a disease) The study will consist of two parts - Part A and Part B. Part A will consist of two treatments: * one dose of PF-07328948 solution to be taken by mouth on day 1. * one cyclosporine 600 mg capsule taken together with a dose of PF-07328948 solution by mouth on day 12. Before study Part A starts, all participants will go through a screening process which may last for a period of up to 28 days. During this period, the participant's medical history and past and current medications will be reviewed. A series of tests will also be performed. If the participants meet all required criteria and want to continue, they will be brought into the study clinic to stay overnight for 17 days. During this period, the experiences of participants receiving the study medicine will be examined. Samples for laboratory assessments will be collected. Vital signs and medical assessments will also be performed. This will help determine if it is safe to take the study medicines together and what happens to these medicines in one's body (called PK assessment). After Part A, participants will be discharged from the clinic. Based upon the results of Part A, study participants may proceed to Part B. If Part B occurs, participants will return to the study clinic and remain in the clinic for 8 days. There will be a gap of at least 7 days between Part A and Part B. Part B will consist of a third treatment: \- clarithromycin 500 mg tablet to be taken 2 times a day for 6 days. On day 4, the tablet will be taken together by mouth with a dose of PF-07328948 solution. During this period, similar laboratory and medical assessments as done in Part A will occur. After Part B, participants will be discharged from the clinic. The participant will be contacted for a follow up visit by telephone about 30 days after final treatment. This is to check up on how the participant is doing and to conclude the study. If only Part A occurs, a participant will be in the study about 44 days. If Part B occurs, a participant will be in the study for about 64 days.
Conditions
- Healthy Adults
Interventions
PF-07328948Drug
single oral dose day 1 and day 12 (Part A) and day 4 (part B)
cyclosporineDrug
600 mg capsule day 12 (Part A)
clarithromycinDrug
500 mg tablets twice daily day 1 to day 6 (Part B)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of PF-07328948Time frame: Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 post-dose
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07328948Time frame: Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 post-dose
- Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of PF-07328948Time frame: Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.